Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1008479

	registered interest
	date	16/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to make flash glucose monitoring technology available to all patients with diabetes across clinical commissioning groups.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	192108
	answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>Following an announcement by NHS England on 14 November 2018, flash glucose monitoring systems will be made available on prescription for all patients with type 1 diabetes who meet National Health Service criteria from April 2019.</p><p> </p><p>No estimate has been made of the potential savings related to making flash glucose monitoring technology available to all patients with diabetes.</p><p> </p><p>A search of the Department’s Ministerial correspondence database has identified 272 items of correspondence from members of the public received in 2018 about flash glucose monitoring. This figure represents correspondence received by the Department’s Ministerial correspondence unit only. The Department has not been able to identify any correspondence specifically from charities.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 192109 192110 question first answered 26/11/2018 17:43:55 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

964009

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of clinical commissioning groups' commissioning of FreeStyle Libre glucose monitoring technology on patients' access to that technology throughout England.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	169910
	answer	answer is ministerial correction date of answer 06/09/2018 answer text <p>New figures from NHS England indicate that the majority, around 140 out of 195 clinical commissioning groups (CCGs) have now approved FreeStyle Libre or uptake. Earlier this year NHS England wrote to CCGs reminding them of their responsibilities and of the guidance that exists when it comes to flash glucose monitoring, and other treatments for people with type 1 diabetes.</p><p> </p><p>NHS England continues to work with CCGs to encourage them to adopt best practice.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/09/2018 10:33:05 answering member 4067 label Biography information for Steve Brine
	tabling member	1538 label Biography information for Rosie Cooper

712468

	registered interest
	date	20/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will make it his policy to make continuous glucose monitors available on the NHS.
	tabling member constituency	Wellingborough
	tabling member printed	Mr Peter Bone
	uin	68467
	answer	answer is ministerial correction date of answer 23/03/2017 answer text <p>Clinical commissioning groups (CCGs) are primarily responsible for commissioning diabetes services to meet the requirements of their populations. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, and are based on the available evidence, taking into account national guidelines. This should include consideration of access to continuous glucose monitoring for people with type 1 diabetes who might benefit from it.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 23/03/2017 09:48:15 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1581 label Biography information for Mr Peter Bone

687062

	registered interest
	date	08/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when NICE plans to report on the availability of FreeStyle Libre on the NHS.
	tabling member constituency	Tynemouth
	tabling member printed	Mr Alan Campbell
	uin	63557
	answer	answer is ministerial correction date of answer 20/02/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) is developing a medtech innovation briefing (MIB) on FreeStyle Libre which it expects to publish in May 2017. NICE MIBs provide information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. They contain no judgement on the value of the technology and they do not contain a recommendation from NICE.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/02/2017 12:01:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	529 label Biography information for Sir Alan Campbell

778221

	registered interest
	date	26/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of flash glucose monitoring on the management of diabetes.
	tabling member constituency	Tynemouth
	tabling member printed	Mr Alan Campbell
	uin	109900
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>Freestyle Libre, a flash glucose monitoring system has been approved for reimbursement on National Health Service prescription from 1 November 2017 through listing in Part IX of the NHS England and Wales Drug Tariff.</p><p> </p><p>The NHS Business Services Authority carries out the assessment of Part IX applications made by manufacturers on behalf, of the Secretary of State for Health, for prescribing at NHS expense by an appropriate practitioner.</p><p> </p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p> </p><p>Any device made available for prescribing to patients through listing in Part IX is required to meet set criteria, namely that the product is safe and of good quality, it is appropriate for general practice and, if relevant, non-medical prescribing, and it is cost effective.</p><p> </p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for clinical commissioning groups (CCGs), who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population and are based on the available evidence and take into account national guidelines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 109901 question first answered 03/11/2017 11:47:02 answering member 4067 label Biography information for Steve Brine
	tabling member	529 label Biography information for Sir Alan Campbell

778222

	registered interest
	date	26/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department takes to ensure that people with diabetes have access to new and emerging technologies as they come to market.
	tabling member constituency	Tynemouth
	tabling member printed	Mr Alan Campbell
	uin	109901
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>Freestyle Libre, a flash glucose monitoring system has been approved for reimbursement on National Health Service prescription from 1 November 2017 through listing in Part IX of the NHS England and Wales Drug Tariff.</p><p> </p><p>The NHS Business Services Authority carries out the assessment of Part IX applications made by manufacturers on behalf, of the Secretary of State for Health, for prescribing at NHS expense by an appropriate practitioner.</p><p> </p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p> </p><p>Any device made available for prescribing to patients through listing in Part IX is required to meet set criteria, namely that the product is safe and of good quality, it is appropriate for general practice and, if relevant, non-medical prescribing, and it is cost effective.</p><p> </p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for clinical commissioning groups (CCGs), who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population and are based on the available evidence and take into account national guidelines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 109900 question first answered 03/11/2017 11:47:02 answering member 4067 label Biography information for Steve Brine
	tabling member	529 label Biography information for Sir Alan Campbell

539582

	registered interest
	date	18/07/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans his Department has to make personal devices for instant monitoring of insulin levels available to people with diabetes on the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	43045
	answer	answer is ministerial correction date of answer 25/07/2016 answer text <p>We are not aware of any clinical utility associated with the instant monitoring of insulin levels. However, continuous glucose monitoring devices can measure glucose levels 24 hours a day and it is for National Health Service commissioners to decide whether to make these available to their local populations.</p><p> </p><p>In August 2015, National Institute for Health and Care Excellence (NICE) published guidelines which recommend that such devices should not be made routinely available to people with Type 1 diabetes unless they are willing to commit to using them at least 70% of the time and to calibrate them as needed (as well as meeting certain other criteria).</p><p> </p><p>NICE has found that, for some people, continuous glucose monitoring can have clinical benefit but generally it is not more effective than current methods of self-monitoring.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 25/07/2016 16:14:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4131 label Biography information for Jim Shannon

856888

	registered interest
	date	07/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on how each devolved nation compares internationally on the annual uptake of insulin pumps for the treatment of diabetes in the last three years.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	131400
	answer	answer is ministerial correction date of answer 14/03/2018 answer text <p>As health is a devolved matter, it would be for the relevant Department from each of the devolved administrations to provide information on the uptake and availability of insulin pumps and other diabetes technologies. The Department works closely with counterparts in the devolved administrations in order to share best practice of treatment and care.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is responsible for producing guidelines for best practice of treatment and care. Treatments such as Continuous Subcutaneous Insulin Infusion (CSII) or ‘insulin pump' therapy may be brought into routine use in the National Health Service after their efficacy, safety, and cost-effectiveness have been appropriately demonstrated.</p><p> </p><p>Health is a devolved matter under the devolution settlements and thus it would be a matter for the devolved administrations to determine their use of diabetic pumps. Devolved administrations would be aware of guidance published by NICE on the use of CSII, and are able to follow these if they choose to do so.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 131401 question first answered 14/03/2018 15:25:23 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

856889

	registered interest
	date	07/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the availability of (a) insulin pumps and (b) other diabetes technologies in each devolved nation for the treatment of diabetes.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	131401
	answer	answer is ministerial correction date of answer 14/03/2018 answer text <p>As health is a devolved matter, it would be for the relevant Department from each of the devolved administrations to provide information on the uptake and availability of insulin pumps and other diabetes technologies. The Department works closely with counterparts in the devolved administrations in order to share best practice of treatment and care.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is responsible for producing guidelines for best practice of treatment and care. Treatments such as Continuous Subcutaneous Insulin Infusion (CSII) or ‘insulin pump' therapy may be brought into routine use in the National Health Service after their efficacy, safety, and cost-effectiveness have been appropriately demonstrated.</p><p> </p><p>Health is a devolved matter under the devolution settlements and thus it would be a matter for the devolved administrations to determine their use of diabetic pumps. Devolved administrations would be aware of guidance published by NICE on the use of CSII, and are able to follow these if they choose to do so.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 131400 question first answered 14/03/2018 15:25:23 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

810654

	registered interest
	date	21/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether his Department plans to introduce automatic insulin delivery devices for people who live with diabetes; and if he will make a statement.
	tabling member constituency	South Antrim
	tabling member printed	Paul Girvan
	uin	120999
	answer	answer is ministerial correction date of answer 09/01/2018 answer text <p>Clinical commissioning groups (CCGs) are primarily responsible for commissioning diabetes services. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, are based on the available evidence, and take into account national guidelines. This would apply to automatic insulin delivery devices, which would need to be both licensed and assessed for clinical and cost-effectiveness.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2018 16:11:10 answering member 4067 label Biography information for Steve Brine
	tabling member	4633 label Biography information for Paul Girvan